Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well cediranib maleate works in treating
patients with endometrial cancer that has failed to respond to initial chemotherapy or has
come back after surgery, radiation therapy, or other forms of treatment. Cediranib maleate
may stop the growth of tumor cells by blocking proteins made by tumors that can stimulate
growth of tumor cells as well as blood vessels in and around tumors.